Q2 2024 Earnings Estimate for Danaher Co. Issued By Leerink Partnrs (NYSE:DHR)

Danaher Co. (NYSE:DHR) – Equities research analysts at Leerink Partnrs lowered their Q2 2024 earnings estimates for shares of Danaher in a report issued on Tuesday, April 23rd. Leerink Partnrs analyst P. Souda now anticipates that the conglomerate will earn $1.56 per share for the quarter, down from their previous estimate of $1.66. The consensus estimate for Danaher’s current full-year earnings is $7.65 per share. Leerink Partnrs also issued estimates for Danaher’s Q2 2025 earnings at $1.87 EPS, Q3 2025 earnings at $1.94 EPS and Q4 2025 earnings at $2.64 EPS.

Several other equities analysts also recently commented on the stock. Robert W. Baird upped their target price on shares of Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research report on Wednesday. Barclays raised their price objective on Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research report on Wednesday. TD Cowen boosted their target price on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday. KeyCorp increased their price target on Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. Finally, Raymond James lifted their price objective on Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. Six research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $269.64.

Danaher Trading Up 0.3 %

DHR stock opened at $246.58 on Friday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.37. Danaher has a 1-year low of $182.09 and a 1-year high of $259.00. The business has a 50 day simple moving average of $248.87 and a two-hundred day simple moving average of $231.16. The company has a market capitalization of $182.64 billion, a price-to-earnings ratio of 41.79, a PEG ratio of 3.78 and a beta of 0.83.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, beating the consensus estimate of $1.72 by $0.20. The business had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The business’s revenue was down 2.6% on a year-over-year basis. During the same period in the previous year, the business earned $2.36 earnings per share.

Danaher Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, April 26th. Investors of record on Thursday, March 28th were issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.44%. This is an increase from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date of this dividend was Wednesday, March 27th. Danaher’s dividend payout ratio is presently 18.31%.

Insiders Place Their Bets

In other news, SVP Georgeann Couchara sold 2,622 shares of the company’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total transaction of $636,280.74. Following the transaction, the senior vice president now owns 4,244 shares of the company’s stock, valued at $1,029,891.48. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, SVP Georgeann Couchara sold 2,622 shares of the business’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the sale, the senior vice president now directly owns 4,244 shares of the company’s stock, valued at $1,029,891.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Teri List sold 3,289 shares of the firm’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total transaction of $816,724.48. Following the completion of the transaction, the director now directly owns 19,726 shares in the company, valued at approximately $4,898,360.32. The disclosure for this sale can be found here. Insiders sold a total of 106,565 shares of company stock valued at $26,641,364 over the last 90 days. Insiders own 11.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of DHR. Cape Investment Advisory Inc. bought a new position in shares of Danaher during the 4th quarter worth $25,000. Tsfg LLC lifted its stake in Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after acquiring an additional 88 shares during the period. BKM Wealth Management LLC bought a new position in Danaher during the 4th quarter worth about $27,000. Wetzel Investment Advisors Inc. purchased a new position in Danaher during the 4th quarter valued at about $29,000. Finally, OFI Invest Asset Management bought a new stake in shares of Danaher in the 3rd quarter valued at about $30,000. Institutional investors own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.